Amcor plc (NYSE: AMCR) — A Packaging Colossus Whose Cheap Equity Is a Levered Bet on Its Own Deleveraging

Independent equity research. Report date: July 4, 2026. Fiscal year ends June 30 (transitioning to December 31 in 2027). All share counts and per-share figures are adjusted for the 1-for-5 reverse split effective January 2026 unless noted. This article takes no position and contains no price target outside the clearly-labeled “Author’s Take” block below. General information only, not investment advice.

⚡ Author’s Take

The author’s own independent opinion and general information — not investment advice. The analysis in Sections 1–15 below carries no position and no price target.

Verdict: HOLD / accumulate-on-weakness sub-$42–44. Medium conviction. A levered, deleveraging special situation with a covered-enough ~5.8% yield — not a compounder, not a value trap, not a short.

Amcor is the world’s largest consumer- and healthcare-packaging company, and after the all-stock Berry Global merger (closed April 2025) it is a ~$35B-enterprise, ~$21B-equity business whose stock screens two ways at once — and both are right. On the enterprise it is not cheap: ~9.5x adjusted EV/EBITDA is the upper half of the plastic-converter peer band (Sonoco ~8x, Crown/Silgan ~8.5x, Sealed Air ~9.5x), which is fair-to-full for a cost-plus converter whose organic volumes have been negative (−1.5% last quarter) and whose only growth engine to FY28 is a one-time $650M synergy program. On the equity it is genuinely cheap: ~11x adjusted EPS ($3.98–4.03 FY26 guide), price-to-sales in the 12th percentile and price-to-book in the 8.5th percentile of its own decade, and a 5.8% dividend. The reconciliation of those two facts is the thesis: the equity is cheap because it is a thin, heavily-levered slice of a fully-valued enterprise, and the bet is that debt paydown transfers enterprise value from creditors to shareholders. If management delivers the $650M synergies and drags net leverage from ~3.8x toward its <3x target by CY2027 without cutting the dividend, the equity re-rates on FCF inflection (~$1.5B today toward a ~$3B FY28 target) even if the EBITDA multiple never moves — and you are paid ~5.8% to wait. That is the accumulate case, and I’d want it sub-$42–44 (trough P/S/P/B, ~6%+ starting yield) for adequate margin of safety, treating $45–52 as fair and fading enthusiasm above ~$55.

Why only HOLD, and why medium conviction: this is a mediocre business — a low-ROIC (~8%, roughly its own cost of capital), ~19%-gross-margin, GDP-minus-volume cost-plus converter with negative tangible book (−$7B), a dividend that eats ~75–80% of a just-cut free-cash-flow guide, and a slow secular plastics-regulation headwind. The “cheapness” is levered-equity optics, not a wide moat on sale; strip the leverage and ~9.5x EBITDA is unremarkable. The framing from the tape supports “bottoming defensive value, not falling knife”: the stock is a low-beta (0.64), zero-momentum, high-dividend-yield-loading bond proxy that round-tripped from ~$67 (2022) to a ~$37 cycle low (May 2026) and has bounced ~22% to ~$45 — five years of dead money where the dividend was the return. Catchy tag: “the packaging world’s biggest merger, priced so the equity only works if the debt gets paid down.” Flips bullish if leverage crosses below 3x on schedule with synergies still running ahead of plan and FCF re-accelerating (a genuine re-rate). Flips bearish if the dividend is frozen/cut, leverage sticks above 3.5x into CY2027, or comparable volumes stay ≤ −1.5% for several more quarters (secular demand loss, not destock) — at which point the 5.8% yield is a value-trap signal, not a floor.

📈 Stock Price Action — Five-Year Event Map

Over the trailing five years Amcor has been dead money that paid you to wait: a split-adjusted round-trip from roughly $60 (2021) → a ~$67 peak (mid-2022) → a ~$37 cycle low (May 2026) → ~$45 today. The stock sits ~33% below its 2022 high, near the low end of a multi-year ~$37–67 range, in a 52-week band of ~$36.69–$50.58, and now yields ~5.8%. All prices below are split-adjusted for the 1-for-5 reverse split (pre-split traded prices ×5). Price moves are Fact; attributed drivers are Interpretation. No price target, no support/resistance, no chart patterns.

Cycle narrative. (1) Amcor peaked in mid-2022 as a defensive staples/pricing-power name while the market fell. (2) The post-COVID destocking wave then took volumes and the multiple down ~35% into an October-2023 low. (3) 2024 brought a volume-led recovery. (4) The November-2024 Berry announcement drew a modestly positive reaction — investors bought the synergy/scale narrative. (5) After the April-2025 close, the integration and ~3.8–4.4x leverage overhang plus a FY25 guide-down (a −11% single-day move on 2025-08-14) pushed the stock to ~$39. (6) The January-2026 1-for-5 reverse split re-based the quote ~5x with no economic effect, and the stock recovered to a ~$50.6 high in February. (7) The Q3 FY26 print (May 7), a free-cash-flow guidance cut, and tariff/demand fears drove the ~$36.7 cycle low. (8) It has since bounced ~22% to ~$45 on defensive-income appeal and a weak-USD tailwind.

1. Executive Summary

Amcor plc is the global #1/#2 supplier of consumer and healthcare packaging — flexible films and laminates, rigid plastic containers, closures, dispensing and pharmaceutical devices, and specialty cartons — for food, beverage, healthcare/pharma, personal care and home-care end-markets. After the all-stock acquisition of Berry Global (closed April 30, 2025; ~$10.4B total consideration; ~43% share dilution), it operates through two reportable segments — Global Flexible Packaging Solutions (~72% of net sales) and Global Rigid Packaging Solutions (~28%) — with pro-forma revenue of ~$24B, ~77,000 employees and manufacturing in ~40 countries. FY2026 (ending June 30) is the first full combined year; the company is also moving its fiscal year-end to December 31 in 2027 and relocating select corporate functions to a new US headquarters in Miami.

The investment reality is a mature, low-growth, capital-intensive commodity-converter wrapped around a genuine but narrow moat. Demand is defensive and sticky — primary packaging for food, drink, medicine and hygiene reorders every consumption cycle, no customer is >10% of sales, and packaging is engineered (“spec’d in”) onto and validated against each customer’s filling line, which creates real switching costs (highest in the qualification-gated healthcare/pharma slice Berry expanded). But the economics are cost-plus: resin, aluminum and film costs pass through to price with a 60–90-day lag, gross margins sit around ~19% (versus ~29–30% for genuine specialty-materials peers Avery Dennison and Sealed Air), and ROIC of ~8% barely covers an estimated ~7–8% cost of capital. Organic volumes have been flat-to-negative for years (−1.5% in the March-2026 quarter). The entire near-term earnings algorithm to FY2028 is a one-time $650M cost-synergy program from Berry (tracking ahead of plan: $270M guided in year one) plus mix and share-count arithmetic — not organic demand.

Financially, the merger created a business with negative tangible equity of ~−$7B (goodwill + intangibles of $18.6B exceed book equity of $11.7B), net debt of $14.27B (~3.8x adjusted / ~4.4x GAAP EBITDA versus a <3x target), and a dividend (~$2.60/share split-adjusted, ~5.8% yield) that consumes ~75–80% of a just-cut free-cash-flow guide of $1.5–1.6B (reduced from $1.8–1.9B on a resin-supply shock and inventory build). Management is competent, not brilliant: the Berry deal was a defensible consolidation at a reasonable pre-synergy multiple (~9–9.5x, ~6–7x post-synergy) with a credible integration track record (Bemis, 2019), incentive comp is genuinely rigorous (FY2024 long-term incentive paid 0%), and buybacks are correctly paused — but there is no insider open-market buying despite a decade-trough stock, and the whole thesis rests on delivering synergies and deleveraging.

On valuation, the equity is cheap where the enterprise is not. At ~9.5x adjusted EV/EBITDA, Amcor sits in the upper half of the converter peer band — full, not cheap, for a no-growth cost-plus business. But the equity trades at ~11x adjusted EPS, price-to-sales in the ~12th percentile and price-to-book in the ~8.5th percentile of its own ten-year history, and yields ~5.8%. The gap is leverage: cheap equity multiples on a thin, levered claim over a fairly-valued enterprise. The market is pricing a levered, no-growth converter that de-levers on schedule — an integration/deleveraging call, not a compounder. What follows evaluates whether that call is likely to pay.

2. Business Overview

What Amcor does. Amcor is a converter: it buys commodity inputs — polymer resins (polyethylene, polypropylene, PET), aluminum foil, paper and fiber, films, inks, adhesives and chemicals — and transforms them into engineered packaging that protects, preserves, dispenses and merchandises a customer’s product. The output spans the two reportable segments the company reorganized into after the Berry close:

• Global Flexible Packaging Solutions (~72% of FY2025 net sales; the segment employs ~42,000 people across ~210 facilities in 36 countries). Flexible and film packaging — multi-layer laminates, mono-material recycle-ready films, pouches, bags, wraps, blister and sterile medical packaging — for food (snacks, confectionery, dairy, coffee, pet food, protein/fresh meat), beverage, healthcare/pharmaceutical (blister packs, sachets, sterile medical films), personal care and home care. This is Amcor’s historical core and the segment where its global scale and material-science depth are strongest.
• Global Rigid Packaging Solutions (~28%; ~34,000 employees across ~213 facilities in 34 countries, pre-full-Berry). Rigid plastic containers, jars, bottles and preforms (carbonated soft drinks, water, juice, sports/dairy drinks, spirits, beer, sauces/dressings/spreads, personal care), plastic caps and closures, dispensing systems, and — enlarged materially by Berry — thin-wall injection-molded containers, healthcare devices and specialty cartons. Berry’s Consumer Packaging (North America and International) and its closures/dispensing franchise folded predominantly into this segment, roughly doubling Amcor’s rigid exposure.

How it makes money. Amcor sells directly, through a dedicated sales force, mostly to large consumer-packaged-goods (CPG), beverage, and pharmaceutical/medical customers. The economic model is spec-in cost-plus conversion: packaging is designed and qualified onto the customer’s filling/production line, and Amcor earns a converting spread over pass-through raw-material costs. Per the 10-K, raw-material cost changes are “generally able to be passed on to customers, including through contractual price mechanisms, over time” — but with a lag, so rising resin squeezes margins temporarily and falling resin flatters them. This is the single most important lens on Amcor: reported revenue swings on resin price, not underlying demand. FY2022 revenue rose +13% chiefly because resin inflation inflated pass-through price; FY2024 fell −7% chiefly because customers destocked pandemic-era inventory. Neither was a share event. The durable read on the business is volume + mix, and there the story is flat-to-negative.

Revenue composition and durability. Demand is defensive and recurring by design. Primary packaging for food, beverages, medicine and hygiene is non-discretionary and consumable-linked — it reorders every product cycle, giving the business a sticky, annuity-like top line without contractual backlog. Geographically (by employee base) the business is ~38% North America, ~35% EMEA, ~15% Asia-Pacific and ~12% Latin America. Healthcare/pharma is the highest-value, stickiest and most qualification-gated slice; the beverage/hot-fill PET rigid business is the most cyclical and volume-elastic. The absence of any >10% customer reduces single-name risk but also caps captive lock-in: large CPG buyers dual-source and press on price at contract renewal.

Berry, in brief. The November-2024-announced, April-2025-closed merger (7.25 Amcor shares per Berry share, all-stock) is the defining feature of the current business. Berry pre-merger generated ~$12.3B of FY2024 sales across four legacy segments (Consumer Packaging International, Consumer Packaging North America, Flexibles, and Health/Hygiene & Specialties). Note that Berry spun its nonwovens/films Health, Hygiene & Specialties business into Magnera (with Glatfelter) in November 2024, before the Amcor close — so the piece folded into Amcor is more weighted to rigid containers, closures/dispensing, and healthcare devices than Berry’s headline segmentation implies. The combination roughly doubled Amcor’s rigid exposure, deepened its healthcare franchise, added in-house recycling capability, and created a business spanning ~140+ countries — while adding ~$7.4B of assumed Berry debt to the balance sheet.

Verdict (§2). A defensive, diversified, globally-scaled but fundamentally commodity-converter business: sticky, recurring, essential-goods demand on one side; cost-plus, resin-pass-through, low-differentiation economics on the other. The revenue is durable; the pricing is not powerful.

3. Industry Dynamics

Structure and size. Global flexible packaging is a ~$270–340B market (source-dependent) growing ~4–5% by value; global rigid plastic packaging is larger; total packaging exceeds $1.1T. Crucially, real volume growth is only ~2–4%, tied to GDP, population and consumption — the value CAGR is inflated by resin pass-through. The industry is fragmented at the aggregate level (thousands of regional converters, plus Amcor, Berry-now-internalized, Sealed Air, Sonoco, Crown Holdings, Silgan, Graphic Packaging, Huhtamaki, Mondi, Constantia, ProAmpac, Winpak, Sigma Plastics and others named in Amcor’s own competitive disclosure) but concentrated at the point of use: only a handful of qualified suppliers serve any given filling line, and for multinationals needing one spec across every region, the set narrows to a few global players.

The capital cycle (Marathon lens). The most favorable structural feature is that supply is broadly rational. The dominant capital event in packaging over the last decade has not been greenfield capacity wars but M&A consolidation — Amcor/Bemis (2019), Amcor/Berry (2025), Berry/RPC, Sonoco/Eviosys, Smurfit Kappa/WestRock — which removes capacity and competitors rather than flooding the market. That is the constructive side of Marathon’s capital cycle: consolidation supports pricing discipline and defends returns in a low-growth commodity industry. Offsetting it: high asset intensity (capex ~$850–900M/year for Amcor post-Berry), a secular ESG/plastics-tax overhang, and volume that barely outpaces population growth. This is an industry where scale leaders consolidate to defend, not expand, returns.

Regulation — the swing structural variable. The EU’s Packaging and Packaging Waste Regulation (PPWR, Reg. 2025/40) entered into force February 2025 and applies from August 2026, with milestones requiring all packaging to be “recyclable by design” (graded A–C) from 2030, minimum recycled content of 30–65% for plastics by 2030, and only the highest recyclability grades permitted from 2038. National plastics taxes, extended-producer-responsibility (EPR) fee modulation, single-use bans, and emerging PFAS restrictions on food-contact materials compound the pressure. The correct read is nuanced: PPWR is a net moat-deepener for scaled R&D players and a threat to laggards. It raises the cost of qualification, penalizes hard-to-recycle multi-material laminates, and forces mono-material redesign plus post-consumer-recycled (PCR) content — which advantages players with material-science depth, recycling assets and capital (Amcor spends ~$180M/year on R&D with ~1,500 R&D staff, and gained in-house recycling from Berry). It is not existential for primary packaging, because food and pharmaceutical safety require the barrier, weight and cost performance that only plastic delivers for most food and all liquids and medicines. But it is a genuine, slow-burn substitution and compliance-cost risk (plastic → fiber at the edges; stranded assets in non-recyclable formats; reformulation capex).

Verdict (§3). Structurally mediocre-to-OK, tilting slightly favorable at the top. The ceiling is low — commodity economics, cost-plus pass-through, ~2–4% volume growth — but the floor is solid: rational supply via consolidation, sticky spec-in demand, defensive essential-goods end-markets, and rising regulatory barriers that favor scale. This is not a great industry; it is a durable, defensible one for the scale leaders, and Amcor is the largest of them.

4. Competitive Position

Naming the moat. In Greenwald’s taxonomy, Amcor’s advantage is a hybrid of economies of scale + customer captivity, and it is real but narrow:

1. Scale economies in a locally/regionally captive business. Amcor operates the largest global flexibles footprint (400+ plants post-Berry), giving it procurement leverage on resin (roughly ~$5B of ~$13B annual procurement is resin), manufacturing density, and the unique ability to serve a multinational CPG or pharma customer with one qualified specification across every region. No competitor matches that global one-stop scale.
2. Switching costs from qualification. Packaging is engineered onto and validated against the customer’s filling line; changing suppliers risks line downtime, re-validation, and — in healthcare and pharmaceuticals — regulatory re-filing. This is a genuine, high barrier in the pharma/medical slice Berry expanded, and a moderate one in high-speed CPG lines. It is weakest in commodity mono-web food packaging and beverage rigid.
3. Intangibles. ~7,000 patents and designs, ~$180M/year of R&D, and material-science/sustainability know-how (mono-material recycle-ready films, PCR integration) increasingly gated by PPWR.

Pressure-testing it against the financials. The moat shows up as margin stability, not margin level. Operating margin held in a ~9–11% band across the FY2020–24 resin cycle — evidence of real pass-through discipline and modest pricing power, better than a pure spot commodity. But the level is the tell: Amcor’s gross margin of ~19% sits roughly 10 points below Avery Dennison’s and Sealed Air’s ~29–30%. That gap is the difference between a scaled cost-plus converter and a genuine specialty-materials differentiator. Amcor cannot command differentiation rents at the blended level; its pricing power is spread-protective, not expansionary. Return metrics confirm mid-pack quality: Amcor’s ROIC ran ~9.5–10.6% in FY2021–24 (5.5% in the merger-depressed FY2025), versus Avery ~13–16%, Crown ~10–12.6%, Sonoco ~6–10.5%, Silgan ~7–9%, and Sealed Air ~9–15%. Amcor is better and steadier than Silgan and recent Sonoco, roughly in line with Crown, and structurally below the true differentiators. (Ignore the reported ROE of 70–160% — that is an artifact of thin/negative tangible equity and years of buybacks, not a quality signal.)

Does Berry strengthen the moat, or just add commodity volume and debt? Mixed, tilting modestly positive. The genuine strategic gains: it deepens the healthcare/pharma and dispensing/device franchise (the highest-barrier, stickiest slice), adds North American rigid and closures scale plus in-house recycling, targets ~$650M of cost synergies, and removes a large competitor from the field. But much of Berry’s consumer packaging is lower-margin commodity rigid, and the deal levered the balance sheet to ~$14.3B net debt and drove tangible book to ~−$7B. So Berry widens the scale-and-healthcare moat more than it deepens the pricing-power one, which is unchanged. It adds scale and a better mix-lever alongside commodity volume and financial risk.

Verdict (§4). A narrow, durable moat — real but modest. Not a wide-moat compounder; a scaled, switching-cost- and scale-protected commodity-plus converter. The advantage is genuine (margin stability through cycles, healthcare qualification barriers, global one-stop scale, rising regulatory barriers) but capped (cost-plus economics, ~19% gross versus ~29–30% for differentiators, low-growth end-markets, price-squeezing dual-sourced customers). The “crowded market with weak differentiation” critique is partly true at the blended level and much less true in healthcare/pharma. If the moat vanished tomorrow, the financial consequence would be margin compression toward commodity spot — which is precisely why margin stability, not margin height, is the moat you can see in the numbers.

5. Growth History and Forward Opportunities

Historical growth — read through the resin lens. Legacy Amcor revenue ran $12.86B (FY21) → $14.54B (FY22, +13%) → $14.69B (FY23, +1%) → $13.64B (FY24, −7%) → $15.01B (FY25, +9% but including only ~two months of Berry). Strip pass-through: the FY22 surge was resin inflation, not volume; the FY24 decline was CPG/healthcare destocking of pandemic safety-stock, not lost share. Underlying volume did not inflect positive through the cycle. FY26 nine-month revenue of $17.11B is +72% reported — but that is almost entirely acquired (~$6.9B of Berry sales net of divestitures), not organic.

Current organic trajectory is negative. Per the Q3 FY2026 call (May 6, 2026), total company comparable volume fell −1.5% (an improvement of ~100bp sequentially from ~−2.5% in Q2). Flexibles comparable volume was −1.5% (developed markets down low-single-digit, emerging markets — Asia mid-single-digit — up; higher pet food and proteins, lower healthcare and other nutrition); Rigid comparable volume was −1.5% (Latin America up mid-single-digit; liquids, foodservice and beauty up; healthcare/nutrition down; a ~−$25M US winter-storm hit to Rigid EBIT). Segment adjusted EBIT: Flexibles $452M (+3% comparable, 13.9% margin) and Rigid $276M (roughly flat, ~13% margin ex-storm). The critical disclosure: “excluding synergies, comparable earnings were broadly in line with the prior year.” In other words, underlying, ex-synergy, ex-acquisition operating profit is flat — all near-term earnings growth is synergies plus price, not organic operating leverage.

Forward drivers. Management points to: (a) Berry growth synergies — cross-selling “systems, not components” across the combined portfolio, a $280M annualized-revenue target over three years, already at >$110M annualized (the flagship example: winning a global GLP-1 oral-dose pharma customer that needed EU blister packaging plus a North American rigid container — a combination only the merged company could offer); (b) healthcare/pharma and protein premiumization; © emerging-market growth (Asia/LatAm mid-single-digit, roughly offsetting developed-market softness); and (d) recycle-ready/more-recyclable materials pulled by sustainability regulation. The “core” portfolio (~$20B post-divestiture across six focus categories — healthcare, beauty & wellness, proteins, liquids, foodservice, pet care) is outperforming the group by ~150bp on volume and grew core EBIT ~+4% YTD on modestly lower volume — again, mix and synergy, not volume.

The EPS growth is real but synergy-driven. FY26 adjusted EPS is guided to $3.98–4.03 (split-adjusted; ~+12% at the midpoint), with Q4 implied ~+20% as it laps the Berry close; nine-month adjusted EPS was $2.79 (+11%). The engine: the synergy program ($270M in FY26, raised from a $260M year-one target; $650M cumulative over three years, of which ~$325M is G&A/procurement by FY28), plus ~$30M of financial synergies and ramping operational synergies. That $650M over three years, on a ~$3.7B adjusted-EBITDA base, is essentially the entire growth algorithm to FY2028.

Verdict (§5). Low-quality, low-organic growth engineered into mid-quality EPS growth by synergies and M&A. Through-cycle organic (volume + mix) growth is low — roughly 0–2% in a good year, negative in destock years; management’s own near-term base case has the consumer “down low-single-digit.” The ~10–12% adjusted-EPS CAGR to FY2028 is a one-time integration dividend that fades to low-single-digit once synergies fully lap. This is not a secular grower; it is a mature, consolidating, cost-plus converter harvesting a large acquisition.

6. Financial Quality

Margins and the GAAP→Adjusted wedge (the central quality-of-earnings issue). Adjusted EBIT margin was ~11.5% in FY2025, rising to ~11.6% in nine-month FY26; adjusted EBITDA margin improved 14.1% → 15.4% on synergies and Berry mix — a real but modest uplift for a low-margin converter. The larger issue is the gap between GAAP and “adjusted.” In FY2025, GAAP net income of $511M became adjusted net income of $1,136M (a $625M add-back), and split-adjusted GAAP EPS of $1.60 became adjusted EPS of $3.56. In nine-month FY26, GAAP net income of $717M became adjusted $1,293M, and GAAP EPS of $1.55 became adjusted $2.79. Adjusted EPS runs ~1.8–2.2x GAAP EPS.

What is in the wedge matters. Some of it is genuinely one-time — the Berry inventory step-up amortization ($133M into Q4 FY25 COGS), transaction costs, and restructuring/integration charges ($262M in nine-month FY26). But the single largest and most recurring add-back is amortization of acquired intangibles — ~$540–550M per year ($411M in nine-month FY26). That is a real, if non-cash, economic cost of an acquisition-driven business model being permanently excluded from “adjusted” earnings. The adjustment is defensible on a cash basis (it is a standard roll-up/converter convention), but the implication is that Amcor’s headline “earnings power” is acquisition-inflated, and GAAP EPS is artificially depressed — which, importantly, is why the stock’s GAAP P/E of ~27–28x badly overstates its richness (see §9).

Free cash flow and the guidance cut. FY2025 generated OCF of $1,390M less capex of $580M = FCF of $810M (adjusted FCF $926M on the company’s definition, down slightly from $952M the prior year). The flag is FY26: management cut the FCF guide from $1.8–1.9B to $1.5–1.6B — a ~$300M / ~17% reduction — on higher-cost inventory held against a resin-supply shock and deferred working-capital release. Nine-month FY26 FCF was actually a −$17M outflow (seasonally back-half loaded, after ~$78M/quarter of transaction/restructuring/integration cash costs), so the full-year $1.5–1.6B relies entirely on a large Q4. Cash conversion itself is not a red flag — CFO/GAAP-NI of 2.7x reflects NI being understated by non-cash amortization, not a negative divergence; CFO/adjusted-NI of ~1.2x is normal.

Returns on capital versus cost of capital — the crux. GAAP ROIC was 5.5% in the merger-depressed FY2025 (versus a 9.5–10.6% history). Normalizing: FY26 full-year adjusted EBIT of ~$2.6–2.7B implies NOPAT of ~$2.1–2.2B at a ~19% tax rate against invested capital of ~$25.9B (debt ~$15.85B + equity $11.66B − cash $1.59B), for an adjusted ROIC of ~8–8.5% — roughly equal to an estimated ~7–8% WACC. In plain terms, pre-synergy the Berry deal is roughly value-neutral: the combined entity earns about its cost of capital. The ~$650M pre-tax synergy program (~$510M after-tax) by FY28 is what lifts ROIC toward ~10% and turns the deal value-accretive. The thesis, financially, rests entirely on synergy delivery.

Verdict (§5/§6 financial quality). Economics improve modestly with scale, but this is a low-margin (adjusted EBIT ~11.6%), low-ROIC (~8%, ≈ WACC), cost-plus converter whose EPS growth is manufactured via synergies, Berry mix and share-count arithmetic rather than organic demand. Adjusted EPS is ~2x GAAP on ~$550M/year of acquired-intangible amortization. This is an average-quality, financial-engineering-adjacent industrial — not a compounder. It is also not low-quality accounting: the add-backs are conventional and cash-honest; the caution is simply that “adjusted earnings power” flatters an acquisition-built model.

7. Capital Allocation

The Berry deal. All-stock, ~$10.4B total consideration (equity to Berry holders $7,897M + replacement awards $310M + Berry debt repaid $2,190M), plus ~$7.4B of assumed Berry debt; 7.25 Amcor shares per Berry share; ~1.0B new Amcor shares issued, roughly +43% dilution (pre-split ~1.45B → ~2.31B shares). Against Berry’s ~$1.9B FY24 adjusted EBITDA, the deal was struck at ~9–9.5x EV/EBITDA pre-synergy and ~6–7x including the $650M synergy target — not an obvious overpay, though it is all-stock using ~11x paper to buy a ~9x asset. The rationale is coherent within the industry logic (§3): scale, procurement leverage, cross-sell, material-science depth, and $650M of pre-tax synergies by end-FY28 (on track: $77M delivered in Q3 FY26 alone). Amcor’s Bemis acquisition (2019, ~$6.8B all-stock, ~$180M synergies delivered) gives a credible integration track record. The fair criticism is that this is serial large all-stock M&A — growth-by-acquisition — in a no-growth industry: the EPS growth is engineered, and the equity base has been diluted materially to buy scale.

Dividend. FY2025 dividends paid were ~$850M; the quarterly rate was raised minimally (split-adjusted $0.6375 → $0.65, ~+2%), preserving a long consecutive-increase streak while signaling caution. The payout is ~72% of adjusted EPS, ~75–80% of the cut adjusted-FCF guide, and >100% of GAAP EPS (161% of FY25 GAAP EPS). The ~5.8% yield itself signals market skepticism about coverage. The dividend is safe but thinly covered, and the FCF-guide cut narrowed the cushion — this is a dividend being defended more than comfortably covered.

Buybacks and dilution. Buybacks are correctly paused (no repurchases in Q4 FY25; no active program) given the leverage and the <3x deleveraging priority. Prior buybacks were modest ($122–744M/year FY20–25). Stock-based compensation is modest ($74M in FY25, ~5% of OCF); the $310M of Berry replacement awards were a one-time purchase-accounting item, not ongoing dilution. Nothing egregious here.

Insider behavior. A Form 4 sweep (60 filings since 2024, across named officers and directors) shows only codes A (grants), M (RSU/option exercises) and F (tax withholding), plus six Form 144 proposed-sale notices — and zero open-market purchases (code P) in 2024–2026. Despite the stock sitting near its cheapest-ever price-to-book, no insider has stepped in to buy. That is a mildly negative tell — routine comp mechanics and planned selling, no conviction.

Incentive alignment. The proxy (DEF 14A, September 2025) is genuinely rigorous. Short-term incentives key off adjusted EBIT, adjusted EPS and adjusted FCF; long-term incentives require constant-currency adjusted-EPS growth (10%/year for full vesting) plus a return-on-average-funds-employed (RoAFE) ≥12% gateway (capital-return discipline) and relative TSR versus a peer group (upper-quartile for maximum). Crucially, FY2024 long-term incentives vested 0% — both the EPS and relative-TSR conditions missed — demonstrating that the plan does not pay for underperformance. CEO share-ownership requirement is 500% of salary, with a clawback in place. This is the right metric set (returns + FCF + relative TSR) and it has teeth.

Verdict (§7). Competent, not brilliant. Berry is a defensible (not value-destructive) consolidation at a reasonable pre-synergy multiple with credible synergy math and a real integration track record — but it is empire-scaling in a no-growth industry, funded by heavy equity issuance, and the entire payoff rests on delivering $650M synergies and deleveraging below 3x. The dividend is safe but barely growing; buybacks are correctly paused; comp is rigorous (the 0% FY24 payout proves it); but there is no insider conviction buying. Management has allocated capital competently — and returns will sit at roughly WACC until the synergies land.

8. Changes and Headwinds — Last Two Years

• The Berry merger (transformational). Announced November 2024, closed April 30, 2025; all-stock; ~$10.4B consideration; ~43% dilution; combined pro-forma sales ~$24B. Doubled rigid exposure, deepened healthcare, added recycling. FY2026 is the first full combined year. This is the thesis.
• 1-for-5 reverse stock split (effective ~January 2026). Shares went from ~2,308M to ~462M; the real current price of ~$45 is post-split. Cosmetic, but essential not to misread price/EPS/dividend (all data feeds are retroactively split-adjusted).
• CEO/CFO transition. Peter Konieczny became permanent CEO in September 2024 (interim from April 2024 after Ron Delia departed for health reasons). The CFO, Stephen Scherger, is Berry’s former CFO — a Berry executive now running combined finance. Berry’s fingerprints on leadership and strategy are heavy.
• Portfolio pruning. Six non-core businesses have been sold or put under agreement (~$500M combined transaction value at ~6x, ~$500M combined annual revenue); all cash proceeds go to debt paydown and the disposals are EPS-neutral. A North American beverage business and specialty containers remain under sale discussion. The goal is to sharpen to a ~$20B higher-return core.
• Fiscal-year change + new HQ. Amcor is moving its fiscal year-end from June 30 to December 31 effective 2027 (“for comparability with peers”), creating a six-month stub reporting period (July 1–December 31, 2026, with guidance to be provided in August 2026 alongside Q4). It is also establishing a new US headquarters in Miami, Florida in 2027 (Switzerland and Australia remain hubs). Watch for one-time reorganization costs and reduced period comparability through the transition.
• Resin / Middle East supply shock (current). Resin spot prices were cited as up “close to 100% in a very short period” on Middle East conflict. Amcor has no Middle East operations, sources <5% of resin from the region, and buys ~65% of resin in North America; it is managing via pass-through (~70% contracted, with improved clauses since 2022–23; ~30% via general price increases) and by holding extra inventory. It expects no material Q4 EPS impact — but this is precisely what cut the FY26 FCF guide by ~$300M (higher-cost inventory / deferred working-capital release). This is the key near-term negative: a self-described working-capital “timing” hit whose reversal is contingent on supply normalizing.
• Destocking (2023–24) is now largely lapped; volumes are improving sequentially but remain negative.
• Plastics regulation (EU PPWR, EPR, PFAS). A slow secular headwind — recyclability mandates, recycled-content requirements, and food-contact PFAS restrictions imply compliance/reformulation cost and a substitution risk (plastic → fiber).
• Guidance revisions FY26. Constructive on earnings (adjusted EPS affirmed at $3.98–4.03); negative on cash (FCF cut ~$300M; year-end leverage guided up to ~3.4–3.5x on lower EBITDA and inventory build).

Verdict (§8). Net mixed, tilting to a de-risking-but-not-yet-proven story. Synergies (ahead of plan), divestitures, and the explicit deleveraging commitment strengthen the thesis; the FCF cut, sticky leverage, resin/Middle-East volatility, negative volumes, and plastics-regulation drift weaken it. Execution is tracking, but the margin of safety on leverage and dividend coverage is thin.

9. Risk Analysis

Catastrophic / total-loss risk: LOW. Amcor is investment-grade (BBB), makes essential-goods packaging (food, pharma, hygiene) with recurring demand, a diversified customer and geographic base, and a hard-asset foundation. The risk here is value erosion — leverage plus no organic growth plus regulation — not solvency. Total loss is extremely unlikely absent a catastrophic covenant/refinancing failure, which is not the base case.

Verdict (§8/§9). The risk profile is financial (leverage, FCF/dividend coverage) and secular (plastics regulation, zero organic volume growth), not existential. The binding constraint is deleveraging while defending a ~5.8% dividend on a cost-plus, no-growth top line.

10. Valuation Discussion

No price target, no recommendation. This section frames embedded expectations and scenarios.

The snapshot. At ~$45, with ~461–462M shares, market capitalization is ~$21B; net debt of $14.27B gives an enterprise value of ~$35B.

Two multiples, two stories.

Converter peer band (ROIC.ai TTM EV/EBITDA): Sealed Air ~9.5x, Crown ~8.5x, Silgan ~8.5x, Sonoco ~8.2x, Graphic Packaging ~6.8x; higher-quality label leader Avery Dennison ~11x. Amcor’s ~9.5x adjusted sits at the top of the commodity-converter cluster, below only Avery — despite Amcor’s larger scale and higher leverage. On the enterprise, then, Amcor is not a bargain.

Reconciling the two stories — the leverage lens. The equity multiples (11x adjusted EPS, trough P/S and P/B, 5.8% yield) look cheap precisely because the equity is a thin, heavily-levered claim on a fairly-valued enterprise: ~$14.3B of the ~$35B EV is debt. The implication — and the core of the bull case — is that deleveraging transfers enterprise value from creditors to shareholders. If Amcor holds ~9.5x EBITDA but pays down ~$1B+/year of debt out of FCF, the equity value compounds mechanically even with a flat multiple; and if synergy delivery + dividend safety earn a re-rating from trough P/S/P/B, the equity gets a second leg. That is a deleveraging call, not a cheap-multiple call — and it is why P/S and P/B (the un-distorted, un-levered-at-the-sales-line tells) matter more here than EV/EBITDA.

Embedded expectations — what must be true to justify ~$35B EV + 5.8% yield: (a) $650M synergies substantially delivered by FY28 (lifting EBITDA toward ~$4.2–4.4B); (b) leverage falls below 3x by CY2027 without a dividend cut or equity raise; © organic volume merely stabilizes (flat to +1–2%) — the market is not paying for organic growth; (d) resin pass-through stays price-cost neutral through the Middle-East shock and the ~$300M working-capital drag reverses; (e) the dividend is held/modestly grown, covered ~1.2–1.5x by FCF as synergies build. What the market is pricing correctly: flat organic volume, no real pricing power, elevated leverage, thin dividend coverage, and a secular plastics overhang. What may be mispriced (both ways): the bull view is that the tape under-credits $650M synergies + non-core-divestiture mix quality + FCF inflection to ~$2.5–3B by FY28 with P/S and P/B at troughs; the bear view is that it over-credits synergy durability and dividend safety, and if volumes stay negative and FCF stays ~$1.5B, both the <3x leverage target and the 5.8% yield are at risk and the multiple de-rates toward ~7x.

Scenarios (illustrative, not targets).

Verdict (§9). Priced as a de-levering, no-growth, cost-plus converter with a well-covered-enough ~5.8% yield: cheap on the equity (P/S and P/B at own-history troughs, ~11x adjusted EPS), fair-to-full on the enterprise (~9.5x adjusted EV/EBITDA, upper half of converter peers), and only optically expensive on GAAP P/E (an amortization artifact). The debate is synergy/deleveraging delivery versus plastics/leverage discount — not growth.

11. Variant Perception

Consensus. A safe, defensive, essential-packaging dividend name digesting a transformational merger — “a boring compounder-lite with a ~5.8% yield and a synergy tailwind.” The camp is split: bulls see a de-rated integration/deleveraging winner; skeptics see a levered, low-growth, cost-plus commodity converter under a plastics-regulation cloud — a potential value trap. The factor tape corroborates the “defensive income” read: Amcor loads positively on the DividendYield and Value factors, carries a low market beta (0.64), shows zero momentum loading, and behaves as a rate-sensitive, weak-USD-benefiting bond proxy. Five-year total return has been roughly flat (income was the return); the recent quarter’s strength is a bounce off the May-2026 cycle low, not sustained momentum.

Strongest bull case. Berry synergies ($650M/3yr, already ahead of plan) + ~$500M+ of non-core divestitures + disciplined pass-through drive ~12% adjusted-EPS growth now and FCF inflection toward ~$2.5–3B by FY28; leverage clears 3x in CY2027; P/S (12th percentile) and P/B (8.5th percentile) sit at decade lows, so any confirmation of synergy durability and dividend safety re-rates the equity while you collect a covered ~5.8% yield. In this view the deleveraging math does the heavy lifting: debt paydown alone compounds equity value even at a flat multiple.

Strongest bear case. A cost-plus commodity converter with no organic volume growth (volumes negative for years), where pricing is pass-through, not power; plastics/PPWR/EPR/PFAS are a slow secular substitution and cost headwind; the balance sheet is stretched (net debt $14.3B, tangible book ≈ −$7B, goodwill $12B); the dividend (161% of FY25 GAAP EPS; ~1.2–1.3x the cut FCF) is defended more than covered; the FCF guide was just cut $300M; and the synergy program is the entire bull case and laps out by FY28 into low-single-digit growth. If volumes stay negative and FCF stalls, the leverage target and the yield are both at risk and the multiple de-rates.

The assumptions that matter — and their falsifiers.

• A1 — Synergies of ~$650M land on schedule. Falsified if the quarterly cumulative-synergy bridge stalls or misses, or “dis-synergies”/customer losses offset the gross number.
• A2 — Deleveraging to <3x by CY2027 without a dividend cut or equity raise. Falsified if leverage stays above ~3.5x into CY2027, or a dividend freeze/cut or equity issuance is announced.
• A3 — Resin pass-through stays price-cost neutral through the shock and the ~$300M working-capital drag reverses. Falsified if a quarter shows material price-cost margin compression, or FCF stays ~$1.5B with no working-capital recovery.
• A4 — Organic volume stabilizes (flat to +1–2%). Falsified if comparable volumes stay ≤ −1.5% for several more quarters (secular demand loss, not destock).
• A5 — Plastics regulation stays a slow burn, not a step-change substitution. Falsified if a major brand-owner mandates fiber/alt-substrate switching at scale, or PPWR/PFAS forces costly reformulation.

Where consensus may be offside. In two directions. It may underrate synergy delivery and the deleveraging math (a positive surprise, given synergies are already ahead of plan and P/S/P/B are at troughs). Or it may overrate dividend safety on a just-cut FCF guide (a negative surprise, if a soft consumer keeps FCF near $1.5B). The factor read frames the stock as levered value / de-rating-reversal with a covered-enough yield — not a momentum growth story.

12. Fact vs. Interpretation Table

13. Open Questions

1. Exact post-full-Berry segment revenue split and healthcare/pharma as a % of group — needed to size the highest-moat slice; the FY26 10-K/segment note will resolve it.
2. Q4 FY26 free cash flow — after a nine-month −$17M outflow, does Q4 deliver the ~$1.5–1.6B implied? Back-half loading is real execution risk.
3. Price versus volume within each segment’s “organic” — management gives volume and comparable EBIT, but resin-price contribution to revenue is not cleanly disclosed.
4. Timing and proceeds of the North American beverage divestiture — the largest remaining non-core piece.
5. Goodwill impairment risk on Rigid/Consumer if volumes stay negative (a non-cash but optically damaging event given negative tangible equity).
6. Stub-period (Jul–Dec 2026) guidance and the FYE transition — how much one-time reorg cost, and how much comparability is lost through the change and the Miami HQ move?
7. Interest-cost creep as sub-4% legacy notes refinance at ~5.45% into a ~$6.3B FY26–28 maturity wall.

14. What Must Be True

Bull case — what must be true, and its single falsification test. The Berry synergies ($650M by FY28) must substantially land, net leverage must fall below 3x by CY2027 without cutting the dividend, and free cash flow must inflect from ~$1.5B toward the ~$3B FY28 target — so that deleveraging transfers enterprise value to the equity and trough P/S/P/B re-rate. Falsification test: if, by the end of CY2026, adjusted net leverage is not on a clear glide-path below ~3.4x and the cumulative-synergy bridge is running behind the $650M/3yr schedule, the deleveraging/re-rating thesis is broken — the equity is then just a levered claim on a stagnant, fully-valued converter.

Bear case — what must be true, and its single falsification test. Organic volumes must stay negative (secular demand loss, not destock), pricing must remain pure pass-through with no power, the FCF cut must persist so the dividend is defended out of the balance sheet rather than covered, and plastics regulation must accelerate substitution — turning the 5.8% yield into a value-trap signal. Falsification test: if comparable volumes turn positive on a sustained basis, FCF recovers to $1.8B+ with the working-capital drag reversing, and leverage crosses below 3x with the dividend intact, the value-trap thesis is broken — Amcor is then a successfully-deleveraged, cash-generative income compounder at a trough multiple.

Source appendix follows below (Appendix B).

APPENDIX A — Standard Diligence Questionnaire — Amcor plc (NYSE: AMCR)

Supplemental to the research memo. Report date July 4, 2026. Fact / Interpretation / Assumption labels applied where material. All per-share figures split-adjusted (1-for-5, January 2026).

General

What thoughtful questions have other investors asked about this company? The recurring investor debates: (1) Is the ~5.8% dividend safe given the FCF-guide cut to $1.5–1.6B and a payout above 100% of GAAP EPS? (2) Will the $650M Berry synergies actually land, and how much leaks back to customers as price? (3) Can Amcor deleverage below 3x by CY2027 without a dividend cut or equity raise? (4) Is plastics regulation (EU PPWR, PFAS) an existential substitution threat or a moat-deepener for scale players? (5) Is organic volume decline cyclical (destock) or secular? (6) Why is there no insider buying at a decade-trough price-to-book? (7) What does the fiscal-year change (to December) and Miami HQ move signal, and what one-time costs come with them?

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Interpretation: Below mid-cycle on volume (comparable volumes −1.5%, destocking lapped but consumer soft), but adjusted EPS is being pushed up by one-time Berry synergies — so reported adjusted EPS is rising into a soft volume environment. Underlying, ex-synergy operating profit is roughly flat. Driven by external environment or internal actions? Both: external (resin costs, consumer volume) sets the backdrop; internal actions (synergies, divestitures, pass-through pricing) drive the near-term earnings growth. How stable are revenues? Very stable in demand terms (essential food/pharma/hygiene packaging, recurring reorder), but reported revenue is volatile because resin pass-through inflates/deflates the top line independent of volume. Outlook for products/services? Low-single-digit real volume growth long-term; mix upgrade toward healthcare and recycle-ready materials. How big is this market — growing, shrinking, domestic or international? ~$270–340B flexibles alone, >$1.1T total packaging; growing ~2–4% by volume; highly international (Amcor ~62% ex-North-America by employees).

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Interpretation: Less, at the top — consolidation (Amcor/Berry, Sonoco/Eviosys, Smurfit/WestRock) is removing competitors and rationalizing supply; but customer bargaining power remains high (dual-sourcing). How profitable is the business (ROIC, ROE)? Adjusted ROIC ~8% (≈ WACC), historical GAAP ROIC 9.5–10.6%; reported ROE (70–160%) is a negative/thin-tangible-equity artifact — ignore it. How profitable is the industry — competitors, barriers? Modestly profitable, low-margin; barriers are qualification/switching costs, scale, and rising regulation, not patents or brands. Can the business be easily understood? Yes — a global converter of commodity inputs into engineered packaging at a spread. Can it be undermined by foreign low-cost labor? Limited — packaging is capital-intensive, freight-sensitive (bulky, low value/weight), and made regionally near customers; not a labor-arbitrage business. Do brands matter? To Amcor’s customers (CPG brand owners) yes; to Amcor itself, no — it is a B2B ingredient supplier, not a consumer brand. Nature of competition? Price/service/qualification-based; spec-in incumbency plus scale. Customers’ switching costs? Real but moderate — line re-qualification, downtime, and (in pharma) regulatory re-filing; highest in healthcare, lowest in commodity food/beverage.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Not materially; if anything the intangibles are over-recognized (Berry purchase-accounting step-ups). Off-balance-sheet liabilities? Operating leases (capitalized), pension (modest, ~$305M obligations), environmental contingencies (PFAS/plastics tail); nothing egregious disclosed. How conservative is the accounting? Adequate but adjusted-earnings-forward — adjusted EPS runs ~1.8–2.2x GAAP, largely on ~$550M/year acquired-intangible amortization (a real non-cash cost excluded from “adjusted”). Cash flow is honest (CFO/adjusted-NI ~1.2x). How CapEx-hungry? Moderately — ~$850–900M/year (~3.5–4% of sales) post-Berry; manageable but not light.

Capital Allocation & Management

How much FCF, and how is it used? ~$1.5–1.6B FY26 guide (cut from $1.8–1.9B); priorities are dividend (~$1.2B), debt paydown (all divestiture proceeds), and paused buybacks. Philosophy? Investment-grade balance sheet, modestly growing dividend, deleverage below 3x, then resume buybacks/bolt-ons. Significant acquisitions recently? Berry (2025, ~$10.4B all-stock, transformational); Bemis (2019). Buying back shares? Paused (correctly, given leverage). Issuing large amounts of new shares to insiders? No — SBC modest ($74M FY25); the ~43% dilution was the all-stock Berry consideration, not insider grants. Compensation policy? Rigorous: STI on adjusted EBIT/EPS/FCF; LTI on constant-currency adjusted-EPS growth + RoAFE ≥12% gateway + relative TSR; FY24 LTI vested 0% (genuine pay-for-performance). CEO ownership requirement 500% of salary; clawback in place. Motivations of management? Aligned on returns and FCF; but no insider open-market buying at trough valuation (mildly negative).

Valuation & Market Data

Is the stock an ADR, MLP, or K-1 issuer? No — Amcor plc is a Jersey-incorporated NYSE-listed ordinary share (also listed on the ASX); not an ADR, MLP or K-1. Note the US-tax character of dividends and any withholding should be confirmed by the holder given the Jersey domicile. Dividend policy? ~$2.60/share split-adjusted (~$0.65/quarter), modestly growing, ~5.8% yield, long consecutive-increase streak. How profitable? Low-margin (adjusted EBIT ~11.6%), low-ROIC (~8%). Is net income diverging from cash from operations? GAAP NI is below CFO (CFO/NI 2.7x) because non-cash amortization depresses NI — an understatement of earnings, not a quality red flag; on an adjusted basis CFO/NI ~1.2x is normal.

Risks & Downside

What would cause the stock to decline? A dividend cut/freeze; leverage sticking above 3.5x; synergy shortfall; persistent negative volumes; a resin-cost/price-cost squeeze; a goodwill impairment; a step-change in plastics-substitution regulation; higher-for-longer rates (bond-proxy de-rating). Risk of catastrophic loss? Low — investment-grade, essential-goods, diversified, hard-asset. Chance of total loss? Very low, absent a covenant/refinancing failure that is not the base case.

Recent News & Events

Has the business environment changed recently? Yes materially: Berry merger closed (April 2025); 1-for-5 reverse split (January 2026); FY26 FCF guide cut ~$300M on a resin-supply shock; fiscal-year-end moving to December (2027) with a Jul–Dec 2026 stub; new Miami HQ; six non-core divestitures (~$500M) with proceeds to debt paydown. Significant acquisitions? Berry (transformational). Change in accounting policies? The fiscal-year change and Berry purchase-accounting are the notable items; no restatements. Recent changes — new markets, facilities, management? New permanent CEO (Konieczny, 2024) and ex-Berry CFO (Scherger); Miami HQ; combined ~140-country footprint; synergy/integration program underway.

APPENDIX B — Source Appendix — Amcor plc (NYSE: AMCR)

Primary sources over secondary; recent over stale. Accessed July 3–4, 2026. Market and aggregator data reconciled to primary filings.

Primary — SEC Filings (Amcor plc, CIK 0001748790)

• FY2025 Form 10-K (fiscal year ended June 30, 2025), filed 2025-08-15 — Item 1 Business (segments, raw materials, competition, employees, geography), Item 1A Risk Factors, Item 7 MD&A, financial statements, Berry purchase-price allocation, debt maturity schedule. https://www.sec.gov/Archives/edgar/data/1748790/000174879025000021/amcr-20250630.htm
• Q3 FY2026 Form 10-Q (quarter ended March 31, 2026), filed 2026-05-07 — balance sheet (goodwill/intangibles, net debt), segment results, Berry PPA detail. https://www.sec.gov/Archives/edgar/data/1748790/000174879026000016/amcr-20260331.htm
• Q2 FY2026 Form 10-Q (Dec 31, 2025), filed 2026-02-04; Q1 FY2026 Form 10-Q (Sep 30, 2025), filed 2025-11-04 — post-split share counts, quarterly progression.
• Q3 FY2026 earnings release (8-K), filed 2026-05-06 — adjusted EPS $0.96 (Q3), $2.79 (9-mo), FY26 guide $3.98–4.03; FCF guide cut to $1.5–1.6B; synergy progress ($77M Q3, $270M FY26 target); adjusted leverage 3.8x. Accession 000174879026000014.
• FY2025 earnings release (8-K), filed 2025-08-14 — original FY26 guidance (adjusted EPS $4.00–4.15 post-split; FCF $1.8–1.9B); FY25 adjusted EPS $3.56; adjusted EBITDA $2,186M. Accession 000174879025000021 (release exhibit).
• DEF 14A proxy, filed 2025-09-23 — executive compensation (STI/LTI metrics: adjusted EBIT/EPS/FCF, RoAFE ≥12% gateway, relative TSR; FY24 LTI vested 0%); ownership requirements; clawback. https://www.sec.gov/Archives/edgar/data/1748790/ (amcr-20250922)
• Form S-4 / merger materials (Berry Global) — 7.25 exchange ratio, all-stock structure, ~$10.4B consideration, pro-forma financials.
• Form 4 corpus (2024–2026) — insider transactions: codes A (grants), M (exercises), F (tax withholding) only; zero code-P open-market purchases; six Form 144 proposed sales.
• dei:EntityCommonStockSharesOutstanding (EDGAR XBRL) — documenting the 1-for-5 reverse split: 2,308,359,941 (10-Q 2025-11-04) → 462,045,690 (10-Q 2026-02-02).

Primary — Company Communications

• Amcor Q3 FY2026 earnings call transcript, 2026-05-06 (Peter Konieczny, CEO; Stephen Scherger, CFO) — volumes −1.5%; ex-synergy earnings “broadly in line”; FY26 guide; synergy bridge ($270M year-1, $650M/3yr); FCF cut and resin/Middle-East commentary; fiscal-year change to December (six-month stub Jul–Dec 2026); Miami HQ; dividend $0.65/quarter.
• Amcor investor relations / press releases — Berry merger announcement (2024-11-19) and close (2025-04-30); reverse split; non-core divestitures; capital-allocation framework. https://www.amcor.com/investors
• Berry Global FY2024 10-K / segment disclosure — pre-merger segment mix; Magnera (HHS) spin-off, November 2024.

Secondary — Industry, Regulation, Market Data

• EU Packaging and Packaging Waste Regulation (PPWR, Reg. (EU) 2025/40) — European Commission (environment.ec.europa.eu); legal analyses (khlaw.com, gleisslutz.com), 2025 — in force 2025-02-11, applies from 2026-08-12; recyclability grades, recycled-content minimums (30–65% by 2030).
• Packaging market sizing — Mordor Intelligence, Fortune Business Insights, Precedence Research, Grand View Research (flexible packaging ~$270–340B, 2025; ~2–4% real volume growth).
• Merger announcement coverage — businesswire.com (2024-11-19); resource-recycling.com (2024-11-19) on segment integration and Magnera.

Quantitative / Market Data (reconciled to filings)

• ROIC.ai — income statement, balance sheet, cash flow, profitability/credit ratios, enterprise value, valuation multiples, earnings-call transcripts (AMCR and peers SEE, SON, CCK, SLGN, GPK, AVY), accessed 2026-07-04. Peer EV/EBITDA (TTM): SEE ~9.5x, CCK ~8.5x, SLGN ~8.5x, SON ~8.2x, GPK ~6.8x, AVY ~11x.
• Valuation percentile screen (own 10-yr history) — P/E ~68th (GAAP-distorted), P/B ~8.5th, P/S ~12th, composite ~29.7th; latest price $45 (2026-07-02).
• 5-year daily price history — split-adjusted OHLC, dividend/split columns, EMAs, beta 0.64; reverse-split row 2026-01-15 (0.200 = 1-for-5).
• Factor / risk model (FactorsToday) — stock-loadings (Materials +0.60, Market +0.56, DividendYield +0.38, Value +0.23, Momentum absent), leaderboard (5-yr return ~−0.19%/yr, maxDD −34%; recent m3/m6 bounce), stock-info (beta 0.64, alpha −0.11, rs_6m +10.5), related-stocks (PPG, SON, CCK, AVY), accessed 2026-07-02/03.
• SEC EDGAR XBRL — revenue, shares outstanding, and reconciliations, authoritative for US-filer figures.

Peer Cross-Reads (public filings)

• Avery Dennison (AVY), International Paper (IP), and Smurfit WestRock (SW) public filings and disclosures — used for the packaging peer valuation band and industry framing.